|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Alvarado-Cabrero I, Hernández-Toriz N and
Paner GP: Clinicopathologic analysis of choriocarcinoma as a pure
or predominant component of germ cell tumor of the testis. Am J
Surg Pathol. 38:111–118. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Smith ZL, Werntz RP and Eggener SE:
Testicular cancer: Epidemiology, diagnosis, and management. Med
Clin North Am. 102:251–264. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sesterhenn IA and Davis CJ Jr: Pathology
of germ cell tumors of the testis. Cancer Control. 11:374–387.
2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Moch H, Amin MB, Berney DM, Compérat EM,
Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR,
et al: The 2022 World Health Organization Classification of tumours
of the urinary system and male genital organs-part A: Renal,
penile, and testicular tumours. Eur Urol. 82:458–468.
2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Humphrey PA: Choriocarcinoma of the
Testis. J Urol. 192:934–935. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pattillo RA: Gestational and
non-gestational trophoblastic neoplasms: New developments in DNA
analysis, metabolic function, diagnosis and treatment. Curr Opin
Obstet Gynecol. 5:486–489. 1993.PubMed/NCBI
|
|
8
|
Ikura Y, Inoue T, Tsukuda H, Yamamoto T,
Ueda M and Kobayashi Y: Primary choriocarcinoma and human chorionic
gonadotrophin-producing giant cell carcinoma of the lung: Are they
independent entities? Histopathology. 36:17–25. 2000.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Verbeek W, Schulten HJ, Sperling M,
Tiesmeier J, Stoop H, Dinjens W, Looijenga L, Wörmann B, Füzesi L
and Donhuijsen K: Rectal adenocarcinoma with choriocarcinomatous
differentiation: Clinical and genetic aspects. Hum Pathol.
35:1427–1430. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ji YS and Park SH: Clinical experience of
male primary choriocarcinoma at the samsung medical center. Cancer
Res Treat. 53:874–880. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Iczkowski KA: Germ cell neoplasms of the
testis: Update for 2022. Semin Diagn Pathol. 40:2–21.
2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Reilley MJ and Pagliaro LC: Testicular
choriocarcinoma: A rare variant that requires a unique treatment
approach. Curr Oncol Rep. 17(2)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pierantoni F, Maruzzo M, Bimbatti D,
Finotto S, Marino D, Galiano A, Basso U and Zagonel V: High dose
chemotherapy followed by autologous hematopoietic stem cell
transplantation for advanced germ cell tumors: State of the art and
a single-center experience. Crit Rev Oncol Hematol.
169(103568)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Goldberg H, Klaassen Z, Chandrasekar T,
Fleshner N, Hamilton RJ and Jewett MAS: Germ cell testicular
tumors-contemporary diagnosis, staging and management of localized
and advanced disease. Urology. 125:8–19. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lobo J, Costa AL, Vilela-Salgueiro B,
Rodrigues Â, Guimarães R, Cantante M, Lopes P, Antunes L, Jerónimo
C and Henrique R: Testicular germ cell tumors: Revisiting a series
in light of the new WHO classification and AJCC staging systems,
focusing on challenges for pathologists. Hum Pathol. 82:113–124.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Malassiné A and Cronier L: Hormones and
human trophoblast differentiation: A review. Endocrine. 19:3–11.
2002.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nistal M, Paniagua R, González-Peramato P
and Reyes-Múgica M: Perspectives in pediatric pathology, chapter
25. Testicular and paratesticular tumors in the pediatric age
group. Pediatr Dev Pathol. 19:471–492. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ramon y Cajal S, Pinango L, Barat A,
Moldenhauer F and Oliva H: Metastatic pure choriocarcinoma of the
testis in an elderly man. J Urol. 137:516–519. 1987.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lavoie JM and Kollmannsberger CK: Current
management of disseminated germ cell tumors. Urol Clin North Am.
46:377–388. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Johnson DE, Appelt G, Samuels ML and Luna
M: Metastases from testicular carcinoma. Study of 78 autopsied
cases. Urology. 8:234–239. 1976.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Martínez-Gallegos JC and Ovalle-Zavala EA:
Thyroid storm associated with testicular choriocarcinoma. Eur J
Case Rep Intern Med. 7(001754)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rejlekova K, Cursano MC, De Giorgi U and
Mego M: severe complications in testicular germ cell tumors: The
choriocarcinoma syndrome. Front Endocrinol (Lausanne).
10(218)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rejlekova K, Kalavska K, Makovnik M,
Hapakova N, Chovanec M, De Angelis V, Obertova J, Palacka P,
Sycova-Mila Z, Mardiak J and Mego M: Factors associated with
choriocarcinoma syndrome development in poor-risk patients with
germ cell tumors. Front Oncol. 12(911879)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hamilton RJ, Canil C, Shrem NS, Kuhathaas
K, Jiang MD, Chung P, North S, Czaykowski P, Hotte S, Winquist E,
et al: Canadian Urological Association consensus guideline:
Management of testicular germ cell cancer. Can Urol Assoc J.
16:155–173. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lorch A, Neubauer A, Hackenthal M, Dieing
A, Hartmann JT, Rick O, Bokemeyer C and Beyer J: High-dose
chemotherapy (HDCT) as second-salvage treatment in patients with
multiple relapsed or refractory germ-cell tumors. Ann Oncol.
21:820–825. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Taza F, Abonour R, Zaid MA, Althouse SK,
Anouti B, Akel R, Hanna NH, Adra N and Einhorn LH: Maintenance oral
etoposide after high-dose chemotherapy (HDCT) for patients with
relapsed metastatic germ-cell tumors (mGCT). Clin Genitourin
Cancer. 21:213–220. 2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Moul JW, Paulson DF, Dodge RK and Walther
PJ: Delay in diagnosis and survival in testicular cancer: Impact of
effective therapy and changes during 18 years. J Urol. 143:520–523.
1990.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kersh CR, Constable WC, Hahn SS, Spaulding
CA, Eisert DR, Jenrette JM, Marks RD and Grayson J: Primary
malignant extragonadal germ cell tumors. An analysis of the effect
of the effect of radiotherapy. Cancer. 65:2681–2685.
1990.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Laflamme P, Doucet C, Sirois C, Kopek N
and Vanhuyse M: Stereotactic radiation therapy for residual
chemorefractory primary mediastinal non-seminomatous germ cell
tumor after surgical thoracotomy. Pract Radiat Oncol. 7:260–263.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Orszaghova Z, Kalavska K, Mego M and
Chovanec M: Overcoming chemotherapy resistance in germ cell tumors.
Biomedicines. 10(972)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kalavska K, Schmidtova S, Chovanec M and
Mego M: Immunotherapy in testicular germ cell tumors. Front Oncol.
10(573977)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Koster R, van Vugt MA, Timmer-Bosscha H,
Gietema JA and de Jong S: Unravelling mechanisms of cisplatin
sensitivity and resistance in testicular cancer. Expert Rev Mol
Med. 15(e12)2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
de Vries G, Rosas-Plaza X, van Vugt MATM,
Gietema JA and de Jong S: Testicular cancer: Determinants of
cisplatin sensitivity and novel therapeutic opportunities. Cancer
Treat Rev. 88(102054)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Galvez-Carvajal L, Sanchez-Munoz A,
Ribelles N, Saez M, Baena J, Ruiz S, Ithurbisquy C and Alba E:
Targeted treatment approaches in refractory germ cell tumors. Crit
Rev Oncol Hematol. 143:130–138. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rosas-Plaza X, de Vries G, Meersma GJ,
Suurmeijer AJH, Gietema JA, van Vugt MATM and de Jong S: Dual
mTORC1/2 inhibition sensitizes testicular cancer models to
cisplatin treatment. Mol Cancer Ther. 19:590–601. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Koster R, di Pietro A, Timmer-Bosscha H,
Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA
and de Jong S: Cytoplasmic p21 expression levels determine
cisplatin resistance in human testicular cancer. J Clin Invest.
120:3594–3605. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Juliachs M, Vidal A, Del Muro XG, Piulats
JM, Condom E, Casanovas O, Graupera M, Germà JR, Villanueva A and
Viñals F: Effectivity of pazopanib treatment in orthotopic models
of human testicular germ cell tumors. BMC Cancer.
13(382)2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Fukuda S, Shirahama T, Imazono Y, Tsushima
T, Ohmori H, Kayajima T, Take S, Nishiyama K, Yonezawa S, Akiba S,
et al: Expression of vascular endothelial growth factor in patients
with testicular germ cell tumors as an indicator of metastatic
disease. Cancer. 85:1323–1330. 1999.PubMed/NCBI
|
|
39
|
Jain A, Brames MJ, Vaughn DJ and Einhorn
LH: Phase II clinical trial of oxaliplatin and bevacizumab in
refractory germ cell tumors. Am J Clin Oncol. 37:450–453.
2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nieto Y, Tu SM, Bassett R, Jones RB,
Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L,
et al: Bevacizumab/high-dose chemotherapy with autologous stem-cell
transplant for poor-risk relapsed or refractory germ-cell tumors.
Ann Oncol. 26:2507–2508. 2015.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Mego M, Cierna Z, Svetlovska D, Macak D,
Machalekova K, Miskovska V, Chovanec M, Usakova V, Obertova J,
Babal P and Mardiak J: PARP expression in germ cell tumours. J Clin
Pathol. 66:607–612. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
De Giorgi U, Schepisi G, Gurioli G, Pisano
C, Basso U, Lolli C, Petracci E, Casadei C, Cecere SC, Attademo L,
et al: Olaparib as salvage treatment for advanced germ cell tumors
after chemotherapy failure: Results of the open-label, single-arm,
IGG-02 phase II trial. J Clin Oncol. 38 (15 suppl)(S5058)2020.
|
|
43
|
Mego M, Svetlovska D, Reckova M, Angelis
D, Kalavska K, Obertova J, Palacka P, Rejlekova K, Sycova-Mila Z,
Chovanec M and Mardiak J: Gemcitabine, carboplatin and veliparib in
multiple relapsed/refractory germ cell tumours: The GCT-SK-004
phase II trial. Invest New Drugs. 39:1664–1670. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hittmair A, Rogatsch H, Hobisch A, Mikuz G
and Feichtinger H: CD30 expression in seminoma. Hum Pathol.
27:1166–1171. 1996.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Emerson RE and Ulbright TM: The use of
immunohistochemistry in the differential diagnosis of tumors of the
testis and paratestis. Semin Diagn Pathol. 22:33–50.
2005.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Giannatempo P, Paolini B, Miceli R, Raggi
D, Nicolai N, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S,
et al: Persistent CD30 expression by embryonal carcinoma in the
treatment time course: Prognostic significance of a worthwhile
target for personalized treatment. J Urol. 190:1919–1924.
2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Berney DM, Shamash J, Pieroni K and Oliver
RT: Loss of CD30 expression in metastatic embryonal carcinoma: The
effects of chemotherapy? Histopathology. 39:382–385.
2001.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Necchi A, Anichini A, Raggi D, Giannatempo
P, Magazzu D, Nicolai N, Colecchia M, Paolini B, Coradeschi E,
Tassi E, et al: Brentuximab vedotin in CD30-Expressing germ cell
tumors after chemotherapy failure. Clin Genitourin Cancer.
14:261–264 e4. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Albany C, Einhorn L, Garbo L, Boyd T,
Josephson N and Feldman DR: Treatment of CD30-Expressing germ cell
tumors and sex cord stromal tumors with brentuximab vedotin:
Identification and report of seven cases. Oncologist. 23:316–323.
2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Fankhauser CD, Curioni-Fontecedro A,
Allmann V, Beyer J, Tischler V, Sulser T, Moch H and Bode PK:
Frequent PD-L1 expression in testicular germ cell tumors. Br J
Cancer. 113:411–413. 2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Cierna Z, Mego M, Miskovska V, Machalekova
K, Chovanec M, Svetlovska D, Hainova K, Rejlekova K, Macak D,
Spanik S, et al: Prognostic value of programmed-death-1 receptor
(PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann
Oncol. 27:300–305. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Lobo J, Rodrigues Â, Guimarães R, Cantante
M, Lopes P, Maurício J, Oliveira J, Jerónimo C and Henrique R:
Detailed characterization of immune cell infiltrate and expression
of immune checkpoint molecules PD-L1/CTLA-4 and MMR proteins in
testicular germ cell tumors disclose novel disease biomarkers.
Cancers (Basel). 11(1535)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sadigh S, Farahani SJ, Shah A, Vaughn D
and Lal P: Differences in PD-L1-Expressing macrophages and immune
microenvironment in testicular germ cell tumors. Am J Clin Pathol.
153:387–395. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Kawahara T, Kawai K, Kojima T, Nagumo Y,
Sakka S, Kandori S, Negoro H, Mathis BJ, Maruo K, Miura K, et al:
Phase II trial of nivolumab monotherapy and biomarker screening in
patients with chemo-refractory germ cell tumors. Int J Urol.
29:741–747. 2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chi EA and Schweizer MT: Durable response
to immune checkpoint blockade in a platinum-refractory patient with
nonseminomatous germ cell tumor. Clin Genitourin Cancer.
15:e855–e857. 2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Loh KP and Fung C: Novel therapies in
platinum-refractory metastatic germ cell tumor: A case report with
a focus on a PD-1 inhibitor. Rare Tumors. 9(6867)2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Han C, Zhou Y, Ma JA, Liu J, Jiang YN and
Zhang HX: A promising treatment option for refractory male primary
choriocarcinoma: Report of two cases. Transl Cancer Res.
9:3054–3060. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Zschabitz S, Lasitschka F, Hadaschik B,
Hofheinz RD, Jentsch-Ullrich K, Gruner M, Jager D and Grullich C:
Response to anti-programmed cell death protein-1 antibodies in men
treated for platinum refractory germ cell cancer relapsed after
high-dose chemotherapy and stem cell transplantation. Eur J Cancer.
76:1–7. 2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Adra N, Einhorn LH, Althouse SK,
Ammakkanavar NR, Musapatika D, Albany C, Vaughn D and Hanna NH:
Phase II trial of pembrolizumab in patients with platinum
refractory germ-cell tumors: A Hoosier Cancer Research Network
Study GU14-206. Ann Oncol. 29:209–214. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Tsimberidou AM, Vo HH, Subbiah V, Janku F,
Piha-Paul S, Yilmaz B, Gong J, Naqvi MF, Tu SM, Campbell M, et al:
Pembrolizumab in patients with advanced metastatic germ cell
tumors. Oncologist. 26:558–e1098. 2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mego M, Svetlovska D, Chovanec M, Rečkova
M, Rejlekova K, Obertova J, Palacka P, Sycova-Mila Z, De Giorgi U
and Mardiak J: Phase II study of avelumab in multiple
relapsed/refractory germ cell cancer. Invest New Drugs. 37:748–754.
2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
McGregor BA, Campbell MT, Xie W, Farah S,
Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD,
Mortazavi A, et al: Results of a multicenter, phase 2 study of
nivolumab and ipilimumab for patients with advanced rare
genitourinary malignancies. Cancer. 127:840–849. 2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Necchi A, Giannatempo P, Raggi D, Mariani
L, Colecchia M, Fare E, Monopoli F, Calareso G, Ali SM, Ross JS, et
al: An open-label randomized phase 2 study of durvalumab alone or
in combination with tremelimumab in patients with advanced germ
cell tumors (APACHE): Results from the first planned interim
analysis. Eur Urol. 75:201–203. 2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
National Library of Medicine (NIH):
Clinical Trials Database: NCT03158064. National Library of
Medicine, Bethesda, MD, 2023. https://www.clinicaltrials.gov/ct2/show/NCT03158064.
|
|
65
|
Apolo AB, Nadal R, Girardi DM, Niglio SA,
Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C,
et al: Phase I study of cabozantinib and nivolumab alone or with
ipilimumab for advanced or metastatic urothelial carcinoma and
other genitourinary tumors. J Clin Oncol. 38:3672–3684.
2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Nikolaou M, Valavanis C, Aravantinos G,
Fountzilas G, Tamvakis N, Lekka I, Arapantoni-Dadioti P, Zizi A,
Ghiconti I, Economopoulos T and Pectasides D: Kit expression in
male germ cell tumors. Anticancer Res. 27 (3B):1685–1688.
2007.PubMed/NCBI
|
|
67
|
Madani A, Kemmer K, Sweeney C, Corless C,
Ulbright T, Heinrich M and Einhorn L: Expression of KIT and
epidermal growth factor receptor in chemotherapy refractory
non-seminomatous germ-cell tumors. Ann Oncol. 14:873–880.
2003.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Durán I, García-Velasco A, Ballestín C,
García E, Martínez-Tello F, Pond GR, García-Carbonero R,
Cortés-Funés H and Paz-Ares L: Expression of EGFR, HER-2/neu and
KIT in germ cell tumours. Clin Transl Oncol. 12:443–449.
2010.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Einhorn LH, Brames MJ, Heinrich MC,
Corless CL and Madani A: Phase II study of imatinib mesylate in
chemotherapy refractory germ cell tumors expressing KIT. Am J Clin
Oncol. 29:12–13. 2006.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Piulats J, Muro X, Huddart R, Aparicio J
and Sanchez M: Phase II multicenter study of imatinib in patients
with chemorefractory germ cell tumors that express c-kit. Cancer
Res. 67 (9 Suppl)(2648)2007.
|
|
71
|
Strohmeyer T, Reissmann P, Cordon-Cardo C,
Hartmann M, Ackermann R and Slamon D: Correlation between
retinoblastoma gene expression and differentiation in human
testicular tumors. Proc Natl Acad Sci USA. 88:6662–6666.
1991.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Vaughn DJ, Hwang WT, Lal P, Rosen MA,
Gallagher M and O'Dwyer PJ: Phase 2 trial of the cyclin-dependent
kinase 4/6 inhibitor palbociclib in patients with retinoblastoma
protein-expressing germ cell tumors. Cancer. 121:1463–1468.
2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Castellano DE, Quinn DI, Feldman DR,
Fizazi K, Garcia del Muro X, Gietema JA, Lauer RC, Ising ME, Aregay
M, Crystal AS and Vaughn DJ: A phase II study of ribociclib in men
with unresectable, incurable teratoma with recent progression. J
Clin Oncol. 37 (7 suppl)(S517)2019.
|
|
74
|
Türeci Ö, Kreuzberg M, Walter K, Wöll S,
Schmitt R, Mitnacht-Kraus R, Nakajo I, Yamada T and Sahin U: The
anti-claudin 6 antibody, IMAB027, induces antibody-dependent
cellular and complement-dependent cytotoxicity in claudin
6-expressing cancer cells. Cancer Res. 78 (13 suppl)(S882)2018.
|
|
75
|
Türeci Ö, Wagner M, Paret C, Kreuzberg MM,
Wöll S, Walter K, Häcker SC, Nakajo I, Yamada T and Sahin U:
Claudin 6 is a carcinoembryonic antigen with cancer stem cell
marker features. Cancer Res. 78 (13_suppl)(S1907)2018.
|
|
76
|
Adra N, Vaughn DJ, Einhorn LH, Hanna NH,
Funt SA, Rosales M, Arozullah A and Feldman DR: A phase II study
assessing the safety and efficacy of ASP1650 in male patients with
relapsed refractory germ cell tumors. Invest New Drugs.
40:1087–1094. 2022.PubMed/NCBI View Article : Google Scholar
|
